Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma (Q34747437)

4 August 2017

0 references

1 reference

title

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma (English)

1 reference

4 August 2017

0 references

0 references

1 reference

4

Vic Hasselblad

1 reference

4 August 2017

7

Timothy J Wilt

1 reference

4 August 2017

David J Samson

1

1 reference

4 August 2017

Jerome Seidenfeld

2

1 reference

4 August 2017

Brian Schmitt

3

1 reference

4 August 2017

Peter C Albertsen

5

1 reference

4 August 2017

Charles L Bennett

6

1 reference

4 August 2017

Naomi Aronson

8

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

4 August 2017

1 reference

4 August 2017

95

1 reference

4 August 2017

2

1 reference

4 August 2017

361-376

1 reference

Is there a best endocrine treatment of prostate cancer?

4 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Combined androgen blockade for the treatment of metastatic cancer of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Combined androgen blockade in the treatment of advanced prostate cancer--an overview. The Scandinavian Prostatic Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Evaluation of total versus partial androgen blockade in the treatment of advanced prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Cost-effectiveness of androgen suppression therapies in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Design of clinical trials on prostate cancer. Introduction

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

A general parametric approach to the meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Meta-analysis of multitreatment studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Combination treatment in M1 prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Combination treatment versus LHRH alone in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Pituitary adrenal and gonadal endocrine suppression for the primary treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10647

7 January 2021

Identifiers

DOI

10.1002/CNCR.10647

1 reference

4 August 2017

1 reference